Published in J Infect Dis on June 01, 1981
Cholera. Clin Microbiol Rev (1995) 12.33
New knowledge on pathogenesis of bacterial enteric infections as applied to vaccine development. Microbiol Rev (1983) 7.16
Volunteer studies of deletion mutants of Vibrio cholerae O1 prepared by recombinant techniques. Infect Immun (1988) 4.44
Purification and characterization of the soluble hemagglutinin (cholera lectin)( produced by Vibrio cholerae. Infect Immun (1982) 3.50
Intestinal immune responses in humans. Oral cholera vaccination induces strong intestinal antibody responses and interferon-gamma production and evokes local immunological memory. J Clin Invest (1991) 2.97
Vibrio cholerae hemagglutinin/lectin/protease hydrolyzes fibronectin and ovomucin: F.M. Burnet revisited. Proc Natl Acad Sci U S A (1983) 2.90
Evaluation in humans of attenuated Vibrio cholerae El Tor Ogawa strain Texas Star-SR as a live oral vaccine. Infect Immun (1984) 2.48
Susceptibility to Vibrio cholerae infection in a cohort of household contacts of patients with cholera in Bangladesh. PLoS Negl Trop Dis (2008) 2.48
Evaluation of the human immune response to outer membrane proteins of Vibrio cholerae. Infect Immun (1984) 2.42
Vibrio cholerae expresses iron-regulated outer membrane proteins in vivo. Infect Immun (1983) 2.28
New model for analysis of mucosal immunity: intestinal secretion of specific monoclonal immunoglobulin A from hybridoma tumors protects against Vibrio cholerae infection. Infect Immun (1991) 2.14
Entamoeba histolytica infection in children and protection from subsequent amebiasis. Infect Immun (2006) 1.99
Protective efficacy in humans of killed whole-vibrio oral cholera vaccine with and without the B subunit of cholera toxin. Infect Immun (1987) 1.89
Oral immunization of dogs with purified cholera toxin, crude cholera toxin, or B subunit: evidence for synergistic protection by antitoxic and antibacterial mechanisms. Infect Immun (1982) 1.87
Single-dose Live Oral Cholera Vaccine CVD 103-HgR Protects Against Human Experimental Infection With Vibrio cholerae O1 El Tor. Clin Infect Dis (2016) 1.70
Successful colonization and immunization of adult rabbits by oral inoculation with Vibrio cholerae O1. Infect Immun (1983) 1.67
Immunology of gut mucosal vaccines. Immunol Rev (2011) 1.59
Antigen-specific memory B-cell responses to Vibrio cholerae O1 infection in Bangladesh. Infect Immun (2009) 1.56
Safety, immunogenicity, and efficacy against cholera challenge in humans of a typhoid-cholera hybrid vaccine derived from Salmonella typhi Ty21a. Infect Immun (1990) 1.55
Analysis of the roles of antilipopolysaccharide and anti-cholera toxin immunoglobulin A (IgA) antibodies in protection against Vibrio cholerae and cholera toxin by use of monoclonal IgA antibodies in vivo. Infect Immun (1993) 1.52
Lipopolysaccharide- and cholera toxin-specific subclass distribution of B-cell responses in cholera. Clin Diagn Lab Immunol (1999) 1.51
Immunization with Vibrio cholerae outer membrane vesicles induces protective immunity in mice. Infect Immun (2008) 1.50
Heterologous antigen expression in Vibrio cholerae vector strains. Infect Immun (1995) 1.41
CVD110, an attenuated Vibrio cholerae O1 El Tor live oral vaccine strain. Infect Immun (1993) 1.35
Protective immunity against Clostridium difficile toxin A induced by oral immunization with a live, attenuated Vibrio cholerae vector strain. Infect Immun (1997) 1.34
Effect of prior experimental human enteropathogenic Escherichia coli infection on illness following homologous and heterologous rechallenge. Infect Immun (1998) 1.23
Protection in rabbits induced by the Texas Star-SR attenuated A-B+ mutant candidate live oral cholera vaccine. Infect Immun (1982) 1.23
Coexpression of the B subunit of Shiga toxin 1 and EaeA from enterohemorrhagic Escherichia coli in Vibrio cholerae vaccine strains. Infect Immun (1997) 1.22
Factors influencing secondary vibriocidal immune responses: relevance for understanding immunity to cholera. Infect Immun (1996) 1.21
Attenuated live cholera vaccine strain CVD 103-HgR elicits significantly higher serum vibriocidal antibody titers in persons of blood group O. Infect Immun (1995) 1.20
Antigen-specific memory B-cell responses in Bangladeshi adults after one- or two-dose oral killed cholera vaccination and comparison with responses in patients with naturally acquired cholera. Clin Vaccine Immunol (2011) 1.20
Determinants of the immunogenicity of live virulent and mutant Vibrio cholerae O1 in rabbit intestine. Infect Immun (1987) 1.20
Identification and characterization of Vibrio cholerae surface proteins by radioiodination. Infect Immun (1985) 1.15
The vaccine candidate Vibrio cholerae 638 is protective against cholera in healthy volunteers. Infect Immun (2005) 1.12
Mucosal immunization with Vibrio cholerae outer membrane vesicles provides maternal protection mediated by antilipopolysaccharide antibodies that inhibit bacterial motility. Infect Immun (2010) 1.12
Memory B cell responses to Vibrio cholerae O1 lipopolysaccharide are associated with protection against infection from household contacts of patients with cholera in Bangladesh. Clin Vaccine Immunol (2012) 1.11
Adoptive transfer of gut mucosal antitoxin memory by isolated B cells 1 year after oral immunization with cholera toxin. Infect Immun (1989) 1.10
In vivo expression and immunoadjuvancy of a mutant of heat-labile enterotoxin of Escherichia coli in vaccine and vector strains of Vibrio cholerae. Infect Immun (1999) 1.08
Comparison of immune responses to the O-specific polysaccharide and lipopolysaccharide of Vibrio cholerae O1 in Bangladeshi adult patients with cholera. Clin Vaccine Immunol (2012) 1.07
Assessment of the duration of protection in Campylobacter jejuni experimental infection in humans. Infect Immun (2010) 1.05
Optimizing the germfree mouse model for in vivo evaluation of oral Vibrio cholerae vaccine and vector strains. Infect Immun (2000) 1.03
Transcutaneous immunization with a Vibrio cholerae O1 Ogawa synthetic hexasaccharide conjugate following oral whole-cell cholera vaccination boosts vibriocidal responses and induces protective immunity in mice. Clin Vaccine Immunol (2012) 1.02
In vitro and in vivo analyses of constitutive and in vivo-induced promoters in attenuated vaccine and vector strains of Vibrio cholerae. Infect Immun (2000) 1.02
Development of a DeltaglnA balanced lethal plasmid system for expression of heterologous antigens by attenuated vaccine vector strains of Vibrio cholerae. Infect Immun (2000) 1.02
Mucosal immunologic responses in cholera patients in Bangladesh. Clin Vaccine Immunol (2011) 1.01
Vibrio cholerae: lessons for mucosal vaccine design. Expert Rev Vaccines (2011) 1.00
Memory T-cell responses to Vibrio cholerae O1 infection. Infect Immun (2009) 0.99
Memory B cell and other immune responses in children receiving two doses of an oral killed cholera vaccine compared to responses following natural cholera infection in Bangladesh. Clin Vaccine Immunol (2012) 0.99
Antigen-specific memory T cell responses after vaccination with an oral killed cholera vaccine in Bangladeshi children and comparison to responses in patients with naturally acquired cholera. Clin Vaccine Immunol (2012) 0.98
Comparison of memory B cell, antibody-secreting cell, and plasma antibody responses in young children, older children, and adults with infection caused by Vibrio cholerae O1 El Tor Ogawa in Bangladesh. Clin Vaccine Immunol (2011) 0.98
Phase 1 evaluation of Vibrio cholerae O1, serotype Inaba, polysaccharide-cholera toxin conjugates in adult volunteers. Infect Immun (1998) 0.96
Monoclonal antibodies to outer membrane antigens of Vibrio cholerae. Infect Immun (1985) 0.96
Vibrio cholerae O1 infection induces proinflammatory CD4+ T-cell responses in blood and intestinal mucosa of infected humans. Clin Vaccine Immunol (2011) 0.94
Immune responses to cholera in children. Expert Rev Anti Infect Ther (2012) 0.93
Immunogenicity of two formulations of oral cholera vaccine comprised of killed whole vibrios and the B subunit of cholera toxin. Infect Immun (1989) 0.93
Antibody-secreting cell responses after Vibrio cholerae O1 infection and oral cholera vaccination in adults in Bangladesh. Clin Vaccine Immunol (2013) 0.92
Immune responses to O-specific polysaccharide and lipopolysaccharide of Vibrio cholerae O1 Ogawa in adult Bangladeshi recipients of an oral killed cholera vaccine and comparison to responses in patients with cholera. Am J Trop Med Hyg (2014) 0.92
A recombinant live attenuated strain of Vibrio cholerae induces immunity against tetanus toxin and Bordetella pertussis tracheal colonization factor. Infect Immun (1998) 0.90
Induction of interleukin-8 in T84 cells by Vibrio cholerae. Infect Immun (2004) 0.89
Assay dependent specificities of monoclonal antibodies to bacterial antigens. Clin Exp Immunol (1986) 0.88
Compared colonizing and immunizing efficiency of toxinogenic (A+ B+) Vibrio cholerae and an A- B+ mutant (Texas Star-SR) studied in adult rabbits. Infect Immun (1984) 0.87
Human immune response to Vibrio cholerae O1 whole cells and isolated outer membrane antigens. Infect Immun (1989) 0.87
Insights from natural infection-derived immunity to cholera instruct vaccine efforts. Clin Vaccine Immunol (2012) 0.86
Vibrio cholerae-induced inflammation in the neonatal mouse cholera model. Infect Immun (2014) 0.85
Comparison of clinical features and immunological parameters of patients with dehydrating diarrhoea infected with Inaba or Ogawa serotypes of Vibrio cholerae O1. Scand J Infect Dis (2010) 0.85
Evaluation in mice of a conjugate vaccine for cholera made from Vibrio cholerae O1 (Ogawa) O-specific polysaccharide. PLoS Negl Trop Dis (2014) 0.80
Cost-effectiveness of oral cholera vaccine in a stable refugee population at risk for epidemic cholera and in a population with endemic cholera. Bull World Health Organ (1998) 0.80
Critical analysis of compositions and protective efficacies of oral killed cholera vaccines. Clin Vaccine Immunol (2014) 0.79
Study of avidity of antigen-specific antibody as a means of understanding development of long-term immunological memory after Vibrio cholerae O1 infection. Clin Vaccine Immunol (2012) 0.79
Frequency of reexposure to Vibrio cholerae O1 evaluated by subsequent vibriocidal titer rise after an episode of severe cholera in a highly endemic area in Bangladesh. Am J Trop Med Hyg (2012) 0.78
Genomic correlates of variability in immune response to an oral cholera vaccine. Eur J Hum Genet (2012) 0.78
Transcriptional responses of intestinal epithelial cells to infection with Vibrio cholerae. Infect Immun (2004) 0.77
Single-Cell Analysis of the Plasmablast Response to Vibrio cholerae Demonstrates Expansion of Cross-Reactive Memory B Cells. MBio (2016) 0.75
Model distinguishability and inference robustness in mechanisms of cholera transmission and loss of immunity. J Theor Biol (2017) 0.75
O-Specific Polysaccharide-Specific Memory B Cell Responses in Young Children, Older Children, and Adults Infected with Vibrio cholerae O1 Ogawa in Bangladesh. Clin Vaccine Immunol (2016) 0.75
Making sense of the cause of Crohn's - a new look at an old disease. F1000Res (2016) 0.75
Oral vaccination against enteric bacterial infections: an overview. Infection (1985) 0.75
Attaching and effacing activities of rabbit and human enteropathogenic Escherichia coli in pig and rabbit intestines. Infect Immun (1983) 12.81
Cholera. Clin Microbiol Rev (1995) 12.33
Escherichia coli that cause diarrhea: enterotoxigenic, enteropathogenic, enteroinvasive, enterohemorrhagic, and enteroadherent. J Infect Dis (1987) 12.26
Escherichia coli strains that cause diarrhoea but do not produce heat-labile or heat-stable enterotoxins and are non-invasive. Lancet (1978) 10.29
Toxin, toxin-coregulated pili, and the toxR regulon are essential for Vibrio cholerae pathogenesis in humans. J Exp Med (1988) 9.19
The diarrheal response of humans to some classic serotypes of enteropathogenic Escherichia coli is dependent on a plasmid encoding an enteroadhesiveness factor. J Infect Dis (1985) 9.18
Global burden of Shigella infections: implications for vaccine development and implementation of control strategies. Bull World Health Organ (1999) 8.93
A DNA probe to identify enterohemorrhagic Escherichia coli of O157:H7 and other serotypes that cause hemorrhagic colitis and hemolytic uremic syndrome. J Infect Dis (1987) 8.19
Detection of an adherence factor of enteropathogenic Escherichia coli with a DNA probe. J Infect Dis (1985) 7.78
New knowledge on pathogenesis of bacterial enteric infections as applied to vaccine development. Microbiol Rev (1983) 7.16
Patterns of adherence of diarrheagenic Escherichia coli to HEp-2 cells. Pediatr Infect Dis J (1987) 7.15
Experimental Campylobacter jejuni infection in humans. J Infect Dis (1988) 7.05
A critical appraisal of 98.6 degrees F, the upper limit of the normal body temperature, and other legacies of Carl Reinhold August Wunderlich. JAMA (1992) 6.88
Plasmid-mediated adhesion in enteropathogenic Escherichia coli. J Pediatr Gastroenterol Nutr (1983) 6.59
Enteropathogenic Escherichia coli of classic serotypes associated with infant diarrhea: epidemiology and pathogenesis. Epidemiol Rev (1984) 5.98
Plasmid-mediated factors conferring diffuse and localized adherence of enteropathogenic Escherichia coli. Infect Immun (1985) 5.42
Epidemic Yersinia enterocolitica infection due to contaminated chocolate milk. N Engl J Med (1978) 5.39
Characterization of enteroadherent-aggregative Escherichia coli, a putative agent of diarrheal disease. J Infect Dis (1988) 5.30
Cholera and other vibrioses in the United States. N Engl J Med (1985) 5.17
Endemic cholera in rural Bangladesh, 1966-1980. Am J Epidemiol (1982) 4.93
Relative efficacy of blood, urine, rectal swab, bone-marrow, and rose-spot cultures for recovery of Salmonella typhi in typhoid fever. Lancet (1975) 4.85
Ethics and international research. BMJ (1997) 4.70
Prevention of diarrhea and pneumonia by zinc supplementation in children in developing countries: pooled analysis of randomized controlled trials. Zinc Investigators' Collaborative Group. J Pediatr (1999) 4.57
Role of the eaeA gene in experimental enteropathogenic Escherichia coli infection. J Clin Invest (1993) 4.53
Enteroaggregative Escherichia coli associated with persistent diarrhea in a cohort of rural children in India. J Infect Dis (1989) 4.52
Volunteer studies of deletion mutants of Vibrio cholerae O1 prepared by recombinant techniques. Infect Immun (1988) 4.44
A sensitive and specific DNA probe to identify enteroaggregative Escherichia coli, a recently discovered diarrheal pathogen. J Infect Dis (1990) 4.43
Summary of an international workshop on typhoid fever. Rev Infect Dis (1986) 4.21
Exclusive breastfeeding reduces acute respiratory infection and diarrhea deaths among infants in Dhaka slums. Pediatrics (2001) 4.05
Role of a 60-megadalton plasmid and Shiga-like toxins in the pathogenesis of infection caused by enterohemorrhagic Escherichia coli O157:H7 in gnotobiotic piglets. Infect Immun (1987) 3.96
A two-year study of bacterial, viral, and parasitic agents associated with diarrhea in rural Bangladesh. J Infect Dis (1980) 3.96
Therapeutic effects of oral zinc in acute and persistent diarrhea in children in developing countries: pooled analysis of randomized controlled trials. Am J Clin Nutr (2000) 3.77
A plasmid of enterohemorrhagic Escherichia coli O157:H7 is required for expression of a new fimbrial antigen and for adhesion to epithelial cells. Infect Immun (1987) 3.76
Handwashing to prevent diarrhea in day-care centers. Am J Epidemiol (1981) 3.75
Inoculum size in shigellosis and implications for expected mode of transmission. J Infect Dis (1989) 3.71
Coli surface antigens 1 and 3 of colonization factor antigen II-positive enterotoxigenic Escherichia coli: morphology, purification, and immune responses in humans. Infect Immun (1984) 3.63
Pathogenesis of Shigella dysenteriae 1 (Shiga) dysentery. J Infect Dis (1973) 3.45
Validation of postmortem interviews to ascertain selected causes of death in children. Int J Epidemiol (1990) 3.42
Meta-analysis of intervention trials on case-management of pneumonia in community settings. Lancet (1992) 3.38
Serum and nasal wash antibodies associated with resistance to experimental challenge with influenza A wild-type virus. J Clin Microbiol (1986) 3.33
Aggregative adherence fimbriae I of enteroaggregative Escherichia coli mediate adherence to HEp-2 cells and hemagglutination of human erythrocytes. Infect Immun (1992) 3.30
Magnitude, kinetics, and duration of vibriocidal antibody responses in North Americans after ingestion of Vibrio cholerae. J Infect Dis (1982) 3.28
Heterogeneity of enteroaggregative Escherichia coli virulence demonstrated in volunteers. J Infect Dis (1995) 3.14
Effect of El Niño and ambient temperature on hospital admissions for diarrhoeal diseases in Peruvian children. Lancet (2000) 3.11
Recombinant nontoxinogenic Vibrio cholerae strains as attenuated cholera vaccine candidates. Nature (1984) 3.08
Diagnostic value of the Widal test in areas endemic for typhoid fever. Am J Trop Med Hyg (1978) 3.06
Giardiasis in day-care centers: evidence of person-to-person transmission. Pediatrics (1977) 3.06
Environmental and human isolates of Vibrio cholerae and Vibrio parahaemolyticus produce a Shigella dysenteriae 1 (Shiga)-like cytotoxin. Lancet (1984) 3.05
Safety, infectivity, immunogenicity, and in vivo stability of two attenuated auxotrophic mutant strains of Salmonella typhi, 541Ty and 543Ty, as live oral vaccines in humans. J Clin Invest (1987) 3.03
Clade B-based HIV-1 vaccines elicit cross-clade cytotoxic T lymphocyte reactivities in uninfected volunteers. Proc Natl Acad Sci U S A (1997) 3.02
Economisation of vaccination against Haemophilus influenzae type b: a randomised trial of immunogenicity of fractional-dose and two-dose regimens. Lancet (1998) 2.98
Rates, timing and causes of neonatal deaths in rural India: implications for neonatal health programmes. Bull World Health Organ (2006) 2.90
Adsorption and growth of Vibrio cholerae on chitin. Infect Immun (1979) 2.90
Zinc supplementation in young children with acute diarrhea in India. N Engl J Med (1995) 2.89
Malnutrition as an underlying cause of childhood deaths associated with infectious diseases in developing countries. Bull World Health Organ (2000) 2.74
From the National Institute of Allergy and Infectious Diseases. Summary of a workshop on enteropathogenic Escherichia coli. J Infect Dis (1983) 2.71
Development and persistence of local and systemic antibody responses in adults given live attenuated or inactivated influenza A virus vaccine. J Clin Microbiol (1986) 2.67
Enzyme-linked immunosorbent assay to measure antibodies to purified heat-labile enterotoxins from human and porcine strains of Escherichia coli and to cholera toxin: application in serodiagnosis and seroepidemiology. J Clin Microbiol (1985) 2.66
Longitudinal studies of infectious diseases and physical growth of children in rural Bangladesh. II. Incidence of diarrhea and association with known pathogens. Am J Epidemiol (1982) 2.65
Incidence and severity of rotavirus and Escherichia coli diarrhoea in rural Bangladesh. Implications for vaccine development. Lancet (1981) 2.65
Failure of sanitary wells to protect against cholera and other diarrhoeas in Bangladesh. Lancet (1976) 2.64
Evaluation of a UDP-glucose-4-epimeraseless mutant of Salmonella typhi as a liver oral vaccine. J Infect Dis (1977) 2.57
Methodological issues in diarrhoeal diseases epidemiology: definition of diarrhoeal episodes. Int J Epidemiol (1991) 2.56
Causes of childhood deaths in Bangladesh: results of a nationwide verbal autopsy study. Bull World Health Organ (1998) 2.53
Oral maintenance therapy for cholera in adults. Lancet (1968) 2.53
Immunity of cholera in man: relative role of antibacterial versus antitoxic immunity. Trans R Soc Trop Med Hyg (1979) 2.51
Predisposition for cholera of individuals with O blood group. Possible evolutionary significance. Am J Epidemiol (1985) 2.49
Diarrhea caused by Escherichia coli that produce only heat-stable enterotoxin. Infect Immun (1977) 2.49
Evaluation in humans of attenuated Vibrio cholerae El Tor Ogawa strain Texas Star-SR as a live oral vaccine. Infect Immun (1984) 2.48
Identification and cloning of a novel plasmid-encoded enterotoxin of enteroinvasive Escherichia coli and Shigella strains. Infect Immun (1995) 2.45
Safety of live oral Salmonella typhi vaccine strains with deletions in htrA and aroC aroD and immune response in humans. Infect Immun (1997) 2.44
Comparison of two assay methods for patterns of adherence to HEp-2 cells of Escherichia coli from patients with diarrhea. J Clin Microbiol (1990) 2.43
Experimental human infections with Giardia lamblia. J Infect Dis (1987) 2.42
Evaluation of the human immune response to outer membrane proteins of Vibrio cholerae. Infect Immun (1984) 2.42
Construction of genetically defined double aro mutants of Salmonella typhi. Vaccine (1991) 2.42
Evaluation of influenza A/Hong Kong/123/77 (H1N1) ts-1A2 and cold-adapted recombinant viruses in seronegative adult volunteers. Infect Immun (1980) 2.42
Shigella enterotoxin 1: an enterotoxin of Shigella flexneri 2a active in rabbit small intestine in vivo and in vitro. J Clin Invest (1995) 2.41